Last 12 months
Inside the activity.
0 purchase rows · 38 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 22 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 7 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 16, 2022 Filed Mar 18, 2022 20:05 UTC |
Donovan Michael PatrickVP Operations
|
GrantRestricted Stock Units · Derivative | 37,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000029 · wf-form4_164763389248721.xml · derivative · entry 4 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,250 Underlying: Common Stock · 37,250 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F5 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F5 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:05 UTC |
Donovan Michael PatrickVP Operations
|
Exercise / conversionRestricted Stock Units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000029 · wf-form4_164763389248721.xml · derivative · entry 3 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:05 UTC |
Donovan Michael PatrickVP Operations
|
Tax withholdingCommon Stock | 1,512 | $7.97 | $12,050.64 |
DisclosureSEC source: 0000805928-22-000029 · wf-form4_164763389248721.xml · nonDerivative · entry 2 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,941 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:05 UTC |
Donovan Michael PatrickVP Operations
|
Exercise / conversionCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000029 · wf-form4_164763389248721.xml · nonDerivative · entry 1 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,453 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2022. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:01 UTC |
Billet IsabelleChief Strategy and BD Officer
|
GrantRestricted Stock Units · Derivative | 23,354 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000027 · wf-form4_164763369289095.xml · derivative · entry 5 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,354 Underlying: Common Stock · 23,354 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F6 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F6 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:01 UTC |
Billet IsabelleChief Strategy and BD Officer
|
GrantEmployee Stock Option (right to purchase) · Derivative | 21,784 | $0.00 Strike: $8.20 | $0.00 |
DisclosureSEC source: 0000805928-22-000027 · wf-form4_164763369289095.xml · derivative · entry 4 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,784 Underlying: Common Stock · 21,784 shares Expires 2032-03-16 F5 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2026 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2024 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:01 UTC |
Billet IsabelleChief Strategy and BD Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000027 · wf-form4_164763369289095.xml · derivative · entry 3 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:01 UTC |
Billet IsabelleChief Strategy and BD Officer
|
Tax withholdingCommon Stock | 2,447 | $7.97 | $19,502.59 |
DisclosureSEC source: 0000805928-22-000027 · wf-form4_164763369289095.xml · nonDerivative · entry 2 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,769 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:01 UTC |
Billet IsabelleChief Strategy and BD Officer
|
Exercise / conversionCommon Stock | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000027 · wf-form4_164763369289095.xml · nonDerivative · entry 1 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,216 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2022. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:09 UTC |
Donovan Michael PatrickVP Operations
|
Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 5,000 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0000805928-22-000021 · wf-form4_164573697659302.xml · derivative · entry 4 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2023-05-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:09 UTC |
Donovan Michael PatrickVP Operations
|
Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 10,000 | $0.00 Strike: $5.09 | $0.00 |
DisclosureSEC source: 0000805928-22-000021 · wf-form4_164573697659302.xml · derivative · entry 3 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2022-12-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:09 UTC |
Donovan Michael PatrickVP Operations
|
Exercise / conversionCommon Stock | 5,000 | $5.45 | $27,250.00 |
DisclosureSEC source: 0000805928-22-000021 · wf-form4_164573697659302.xml · nonDerivative · entry 2 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,453 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:09 UTC |
Donovan Michael PatrickVP Operations
|
Exercise / conversionCommon Stock | 10,000 | $5.09 | $50,900.00 |
DisclosureSEC source: 0000805928-22-000021 · wf-form4_164573697659302.xml · nonDerivative · entry 1 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,453 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:14 UTC |
Zaderej Karen L.Director · CEO
|
GrantCommon Stock | 13,978 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000015 · wf-form4_164513242186330.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 940,383 F1 · shares: This reflects the number of shares that became vested as of February 15, 2022 upon the attainment of certain performance criteria. F2 · balance_after: Includes 728 shares acquired under the Axogen stock purchase plan on December 31, 2021. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:11 UTC |
Scopelianos AngeloChief R&D Officer
|
Tax withholdingCommon Stock | 400 | $8.42 | $3,368.00 |
DisclosureSEC source: 0000805928-22-000013 · wf-form4_164513225128430.xml · nonDerivative · entry 2 Scopelianos Angelo · CIK 0001751541 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,950 F3 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 15, 2022. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:11 UTC |
Scopelianos AngeloChief R&D Officer
|
GrantCommon Stock | 1,325 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000013 · wf-form4_164513225128430.xml · nonDerivative · entry 1 Scopelianos Angelo · CIK 0001751541 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,350 F1 · shares: This reflects the number of shares that became vested as of February 15, 2022 upon the attainment of certain performance criteria. F2 · balance_after: Includes 41 shares acquired under the Axogen stock purchase plan on December 31, 2021. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:12 UTC |
Sandberg EricChief Commercial Officer
|
Tax withholdingCommon Stock | 762 | $8.42 | $6,416.04 |
DisclosureSEC source: 0000805928-22-000014 · wf-form4_164513232552416.xml · nonDerivative · entry 2 Sandberg Eric · CIK 0001764446 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,310 F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 15, 2022. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:12 UTC |
Sandberg EricChief Commercial Officer
|
GrantCommon Stock | 2,531 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000014 · wf-form4_164513232552416.xml · nonDerivative · entry 1 Sandberg Eric · CIK 0001764446 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,072 F1 · shares: This reflects the number of shares that became vested as of February 15, 2022 upon the attainment of certain performance criteria. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:09 UTC |
MARIANI PETER JEVP & Chief Financial Officer
|
Tax withholdingCommon Stock | 950 | $8.42 | $7,999.00 |
DisclosureSEC source: 0000805928-22-000011 · wf-form4_164513213910257.xml · nonDerivative · entry 2 MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,353 F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 15, 2022. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:09 UTC |
MARIANI PETER JEVP & Chief Financial Officer
|
GrantCommon Stock | 3,157 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000011 · wf-form4_164513213910257.xml · nonDerivative · entry 1 MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,303 F1 · shares: This reflects the number of shares that became vested as of February 15, 2022 upon the attainment of certain performance criteria. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:08 UTC |
Friedman Mark LouisVP Regulatory Affairs & Policy
|
Tax withholdingCommon Stock | 357 | $8.42 | $3,005.94 |
DisclosureSEC source: 0000805928-22-000010 · wf-form4_164513208300927.xml · nonDerivative · entry 2 Friedman Mark Louis · CIK 0001531023 · VP Regulatory Affairs & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,845 F3 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 15, 2022. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:08 UTC |
Friedman Mark LouisVP Regulatory Affairs & Policy
|
GrantCommon Stock | 1,181 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000010 · wf-form4_164513208300927.xml · nonDerivative · entry 1 Friedman Mark Louis · CIK 0001531023 · VP Regulatory Affairs & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,202 F1 · shares: This reflects the number of shares that became vested as of February 15, 2022 upon the attainment of certain performance criteria. F2 · balance_after: Includes 1,569 shares acquired under the Axogen stock purchase plan on December 31, 2021. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:10 UTC |
MARTINEZ MARIA D.Chief Human Resources Officer
|
Tax withholdingCommon Stock | 400 | $8.42 | $3,368.00 |
DisclosureSEC source: 0000805928-22-000012 · wf-form4_164513219698637.xml · nonDerivative · entry 2 MARTINEZ MARIA D. · CIK 0001633672 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,656 F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 15, 2022. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:10 UTC |
MARTINEZ MARIA D.Chief Human Resources Officer
|
GrantCommon Stock | 1,325 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000012 · wf-form4_164513219698637.xml · nonDerivative · entry 1 MARTINEZ MARIA D. · CIK 0001633672 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,056 F1 · shares: This reflects the number of shares that became vested as of February 15, 2022 upon the attainment of certain performance criteria. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:06 UTC |
Donovan Michael PatrickVP Operations
|
Tax withholdingCommon Stock | 205 | $8.42 | $1,726.10 |
DisclosureSEC source: 0000805928-22-000009 · wf-form4_164513199641018.xml · nonDerivative · entry 2 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,453 F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 15, 2022. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:06 UTC |
Donovan Michael PatrickVP Operations
|
GrantCommon Stock | 675 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000009 · wf-form4_164513199641018.xml · nonDerivative · entry 1 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,658 F1 · shares: This reflects the number of shares that became vested as of February 15, 2022 upon the attainment of certain performance criteria. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:03 UTC |
Billet IsabelleChief Strategy and BD Officer
|
Tax withholdingCommon Stock | 447 | $8.42 | $3,763.74 |
DisclosureSEC source: 0000805928-22-000007 · wf-form4_164513181764016.xml · nonDerivative · entry 2 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,716 F3 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 15, 2022. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:03 UTC |
Billet IsabelleChief Strategy and BD Officer
|
GrantCommon Stock | 1,325 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000007 · wf-form4_164513181764016.xml · nonDerivative · entry 1 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,163 F1 · shares: This reflects the number of shares that became vested as of February 15, 2022 upon the attainment of certain performance criteria. F2 · balance_after: Includes 654 shares acquired under the Axogen stock purchase plan on December 31, 2021. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:05 UTC |
DeVinney Erick WayneVP Peripheral Nerve Science
|
Tax withholdingCommon Stock | 357 | $8.42 | $3,005.94 |
DisclosureSEC source: 0000805928-22-000008 · wf-form4_164513189026580.xml · nonDerivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,075 F3 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 15, 2022. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:05 UTC |
DeVinney Erick WayneVP Peripheral Nerve Science
|
GrantCommon Stock | 1,181 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000008 · wf-form4_164513189026580.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,432 F1 · shares: This reflects the number of shares that became vested as of February 15, 2022 upon the attainment of certain performance criteria. F2 · balance_after: Includes 2 shares acquired under the Axogen stock purchase plan on December 31, 2021. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:33 UTC |
Zaderej Karen L.Director · CEO
|
Exercise / conversionRestricted Stock Units · Derivative | 4,400 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000185 · wf-form4_164081358767730.xml · derivative · entry 3 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,400 Underlying: Common Stock · 8,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F4 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:33 UTC |
Zaderej Karen L.Director · CEO
|
Tax withholdingCommon Stock | 1,752 | $9.74 | $17,064.48 |
DisclosureSEC source: 0000805928-21-000185 · wf-form4_164081358767730.xml · nonDerivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 925,677 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:33 UTC |
Zaderej Karen L.Director · CEO
|
Exercise / conversionCommon Stock | 4,400 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000185 · wf-form4_164081358767730.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 927,429 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that vested on December 27, 2021. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:31 UTC |
Scopelianos AngeloChief R&D Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 1,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000184 · wf-form4_164081344903243.xml · derivative · entry 3 Scopelianos Angelo · CIK 0001751541 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,150 Underlying: Common Stock · 2,300 shares Expires 2022-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F4 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:31 UTC |
Scopelianos AngeloChief R&D Officer
|
Tax withholdingCommon Stock | 286 | $9.74 | $2,785.64 |
DisclosureSEC source: 0000805928-21-000184 · wf-form4_164081344903243.xml · nonDerivative · entry 2 Scopelianos Angelo · CIK 0001751541 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,984 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:31 UTC |
Scopelianos AngeloChief R&D Officer
|
Exercise / conversionCommon Stock | 1,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000184 · wf-form4_164081344903243.xml · nonDerivative · entry 1 Scopelianos Angelo · CIK 0001751541 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,270 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that vested on December 27, 2021. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:30 UTC |
MARTINEZ MARIA D.Chief Human Resources Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 1,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000183 · wf-form4_164081338999506.xml · derivative · entry 3 MARTINEZ MARIA D. · CIK 0001633672 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,150 Underlying: Common Stock · 2,300 shares Expires 2022-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F4 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:30 UTC |
MARTINEZ MARIA D.Chief Human Resources Officer
|
Tax withholdingCommon Stock | 286 | $9.74 | $2,785.64 |
DisclosureSEC source: 0000805928-21-000183 · wf-form4_164081338999506.xml · nonDerivative · entry 2 MARTINEZ MARIA D. · CIK 0001633672 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,731 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:30 UTC |
MARTINEZ MARIA D.Chief Human Resources Officer
|
Exercise / conversionCommon Stock | 1,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000183 · wf-form4_164081338999506.xml · nonDerivative · entry 1 MARTINEZ MARIA D. · CIK 0001633672 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,017 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that vested on December 27, 2021. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:28 UTC |
MARIANI PETER JEVP & Chief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 2,625 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000182 · wf-form4_164081332473376.xml · derivative · entry 3 MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,625 Underlying: Common Stock · 5,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F4 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F4 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:28 UTC |
MARIANI PETER JEVP & Chief Financial Officer
|
Tax withholdingCommon Stock | 648 | $9.74 | $6,311.52 |
DisclosureSEC source: 0000805928-21-000182 · wf-form4_164081332473376.xml · nonDerivative · entry 2 MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,146 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:28 UTC |
MARIANI PETER JEVP & Chief Financial Officer
|
Exercise / conversionCommon Stock | 2,625 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000182 · wf-form4_164081332473376.xml · nonDerivative · entry 1 MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,794 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that vested on December 27, 2021. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:23 UTC |
Friedman Mark LouisVP Regulatory Affairs & Policy
|
Exercise / conversionRestricted Stock Units · Derivative | 1,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000181 · wf-form4_164081298746377.xml · derivative · entry 3 Friedman Mark Louis · CIK 0001531023 · VP Regulatory Affairs & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,150 Underlying: Common Stock · 2,300 shares Expires 2022-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F4 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:23 UTC |
Friedman Mark LouisVP Regulatory Affairs & Policy
|
Tax withholdingCommon Stock | 286 | $9.74 | $2,785.64 |
DisclosureSEC source: 0000805928-21-000181 · wf-form4_164081298746377.xml · nonDerivative · entry 2 Friedman Mark Louis · CIK 0001531023 · VP Regulatory Affairs & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,452 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:23 UTC |
Friedman Mark LouisVP Regulatory Affairs & Policy
|
Exercise / conversionCommon Stock | 1,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000181 · wf-form4_164081298746377.xml · nonDerivative · entry 1 Friedman Mark Louis · CIK 0001531023 · VP Regulatory Affairs & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,738 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that vested on December 27, 2021. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:21 UTC |
Donovan Michael PatrickVP Operations
|
Exercise / conversionRestricted Stock Units · Derivative | 1,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000180 · wf-form4_164081287971437.xml · derivative · entry 3 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,150 Underlying: Common Stock · 2,300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F4 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F4 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:21 UTC |
Donovan Michael PatrickVP Operations
|
Tax withholdingCommon Stock | 286 | $9.74 | $2,785.64 |
DisclosureSEC source: 0000805928-21-000180 · wf-form4_164081287971437.xml · nonDerivative · entry 2 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,983 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:21 UTC |
Donovan Michael PatrickVP Operations
|
Exercise / conversionCommon Stock | 1,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000180 · wf-form4_164081287971437.xml · nonDerivative · entry 1 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,269 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that vested on December 27, 2021. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:17 UTC |
DeVinney Erick WayneVP Peripheral Nerve Science
|
Exercise / conversionRestricted Stock Units · Derivative | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000179 · wf-form4_164081264670254.xml · derivative · entry 3 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750 Underlying: Common Stock · 1,500 shares Expires 2022-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F4 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:17 UTC |
DeVinney Erick WayneVP Peripheral Nerve Science
|
Tax withholdingCommon Stock | 187 | $9.74 | $1,821.38 |
DisclosureSEC source: 0000805928-21-000179 · wf-form4_164081264670254.xml · nonDerivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,249 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.